Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
Kivu Bioscience Inc.
Hoffmann-La Roche
Bayer
ViroMissile, Inc.
AstraZeneca
MacroGenics
Adela, Inc
Perspective Therapeutics
Ocellaris Pharma, Inc.
Eli Lilly and Company
Var2 Pharmaceuticals
Tanabe Pharma America, Inc.
HiFiBiO Therapeutics
Tango Therapeutics, Inc.
Tango Therapeutics, Inc.
Bayer
HiFiBiO Therapeutics
Actym Therapeutics, Inc.
AVM Biotechnology Inc
Valo Therapeutics Oy
Epkin
Eli Lilly and Company
Lantheus Medical Imaging
Turning Point Therapeutics, Inc.
Telix Pharmaceuticals (Innovations) Pty Limited
PharmaMar
Eli Lilly and Company
Hutchmed
Elevation Oncology
IGM Biosciences, Inc.
Labcorp Corporation of America Holdings, Inc
Intensity Therapeutics, Inc.
Cybrexa Therapeutics
Agenus Inc.
Cyteir Therapeutics, Inc.
GI Innovation, Inc.
TopAlliance Biosciences
Actuate Therapeutics Inc.
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai PerHum Therapeutics Co., Ltd.
NantCell, Inc.
Xencor, Inc.
Gene Surgery LLC
TransThera Sciences (Nanjing), Inc.
Pfizer
DNAtrix, Inc.
Celon Pharma SA
Adaptimmune
Corvus Pharmaceuticals, Inc.